Cargando…

Risk prediction model for major adverse cardiovascular events (MACE) during hospitalization in patients with coronary heart disease based on myocardial energy metabolic substrate

BACKGROUND: The early attack of coronary heart disease (CHD) is very hidden, and clinical symptoms generally do not appear until cardiovascular events occur. Therefore, an innovative method is needed to judge the risk of cardiovascular events and guide clinical decision conveniently and sensitively....

Descripción completa

Detalles Bibliográficos
Autores principales:	Na, Li, Lin, Jia, Kuiwu, Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189060/ https://www.ncbi.nlm.nih.gov/pubmed/37206105 http://dx.doi.org/10.3389/fcvm.2023.1137778

Ejemplares similares

Current Progress of Studies of Coronary CT for Risk Prediction of Major Adverse Cardiovascular Event (MACE)
por: Zheng, Jianan, et al.
Publicado: (2021)

Serum FGF21 Levels Predict the MACE in Patients With Myocardial Infarction After Coronary Artery Bypass Graft Surgery
por: Xie, Wei, et al.
Publicado: (2022)

MACE in the Race: A Canadian Perspective on Major Adverse Cardiac Events (MACE) During Running
por: Abrahim, Mohammed
Publicado: (2022)

Development and Validation of a Nomogram of In-hospital Major Adverse Cardiovascular and Cerebrovascular Events in Patients With Acute Coronary Syndrome
por: Bo, Xiangwei, et al.
Publicado: (2021)

Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease
por: Dregoesc, Mihaela Ioana, et al.
Publicado: (2022)

Prediction models for major adverse cardiovascular events following ST-segment elevation myocardial infarction and subgroup-specific performance
por: Chen, Weiyao, et al.
Publicado: (2023)

Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study
por: Farshidi, Hossein, et al.
Publicado: (2018)

Serum YKL-40 in coronary heart disease: linkage with inflammatory cytokines, artery stenosis, and optimal cut-off value for estimating major adverse cardiovascular events
por: Song, Mowei, et al.
Publicado: (2023)

Risk factors for major adverse cardiovascular events after coronary artery bypass grafting using radial artery grafts
por: Xia, Tianyu, et al.
Publicado: (2023)

A prediction model for major adverse cardiovascular events in patients with heart failure based on high-throughput echocardiographic data
por: Sun, Qinliang, et al.
Publicado: (2022)

Plasma Big Endothelin-1 Level Predicted 5-Year Major Adverse Cardiovascular Events in Patients With Coronary Artery Ectasia
por: Cai, Zhongxing, et al.
Publicado: (2021)

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation
por: de los Reyes-García, Ascensión M., et al.
Publicado: (2023)

Estimation of Major Adverse Cardiovascular Events in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Risk Prediction Score Model From a Derivation and Validation Study
por: Zhao, Xiaoxiao, et al.
Publicado: (2020)

The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention
por: Giantini, Astuti, et al.
Publicado: (2023)

Construction and evaluation of nomogram model for individualized prediction of risk of major adverse cardiovascular events during hospitalization after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction
por: Fang, Caoyang, et al.
Publicado: (2022)

4423 Impact of Gender on High On-Treatment Platelet Reactivity (HPR) and Major Adverse Cardiovascular Events (MACEs) in Caribbean Hispanic patients using Clopidogrel
por: Nunez Medina, Hector Jose, et al.
Publicado: (2020)

Editorial: Advances in predicting future adverse coronary events: the role of cardiovascular imaging and coronary physiology indices
por: Seitun, Sara, et al.
Publicado: (2023)

The hemoglobin glycation index predicts the risk of adverse cardiovascular events in coronary heart disease patients with type 2 diabetes mellitus
por: Xu, Shuai, et al.
Publicado: (2022)

Comparison of conventional scoring systems to machine learning models for the prediction of major adverse cardiovascular events in patients undergoing coronary computed tomography angiography
por: Ghorashi, Seyyed Mojtaba, et al.
Publicado: (2022)

Beyond MACE: a multidimensional approach to outcomes in clinical trials for older adults with stable ischemic heart disease
por: Kalra, Kriti, et al.
Publicado: (2023)

Early long-term low-dosage colchicine and major adverse cardiovascular events in patients with acute myocardial infarction: a systematic review and meta-analysis
por: Zhou, Yifang, et al.
Publicado: (2023)

A prediction model for major adverse cardiovascular events (MACE) in patients with coronavirus disease 2019 (COVID-19)
por: Huang, Dong, et al.
Publicado: (2022)

Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial
por: Ma, Teng, et al.
Publicado: (2023)

Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis
por: Muñoz-Bravo, Carlos, et al.
Publicado: (2023)

Association Between Heart Rate and Major Adverse Cardiovascular Events Among 9,991 Hypertentive Patients: A Multicenter Retrospective Follow-Up Study
por: Sun, Ningling, et al.
Publicado: (2021)

Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes
por: Xie, Gaoqiang, et al.
Publicado: (2017)

Prediction of major adverse cardiovascular events in patients with acute coronary syndrome: Development and validation of a non-invasive nomogram model based on autonomic nervous system assessment
por: Wang, Jun, et al.
Publicado: (2022)

Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights
por: Marsal, Josep Ramon, et al.
Publicado: (2022)

Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)
por: Chen, Dongqing, et al.
Publicado: (2023)

Association Between Circulating Retinol-Binding Protein 4 and Adverse Cardiovascular Events in Stable Coronary Artery Disease
por: Qian, Ke, et al.
Publicado: (2022)

Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials
por: Deng, Chang-Jiang, et al.
Publicado: (2023)

Epicardial fat volume, an independent risk factor for major adverse cardiovascular events, had an incremental prognostic value to myocardial perfusion imaging in Chinese populations with suspected or known coronary artery disease with a normal left ventricular ejection fraction
por: Yang, Le, et al.
Publicado: (2023)

Interactions of ST-elevation myocardial infarction, age, and sex and the risk of major adverse cardiovascular events among Chinese adults: a secondary analysis of a single-centre prospective cohort
por: Wang, Cuiping, et al.
Publicado: (2022)

Leukocyte Telomere Length Shortening Implies Plaque Instability and Major Adverse Cardiovascular Events in Patients With Angiographically Intermediate Lesions
por: Zhang, Alian, et al.
Publicado: (2022)

Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans
por: Sun, Ji, et al.
Publicado: (2022)

Association of platelet-to-lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-centre retrospective cohort study
por: Maimaiti, Ailifeire, et al.
Publicado: (2019)

The Usefulness of C-Reactive Protein to Albumin Ratio in the Prediction of Adverse Cardiovascular Events in Coronary Chronic Total Occlusion Undergoing Percutaneous Coronary Intervention
por: Cheng, Lele, et al.
Publicado: (2021)

Comparison of HEAR and HEART Scores for Major Adverse Cardiovascular Events
por: Uyan, Umut
Publicado: (2023)

Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin
por: Sardu, Celestino, et al.
Publicado: (2019)

Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial
por: Shi, Haiming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qhprk9a1j09gfhnh2iqvfqpbi6